Abstract
Antiemetic treatment should be considered for breast cancer patients receiving moderately emetogenic chemotherapy. Although the extent of chemotherapy‐induced emesis is largely dependent on the emetogenic potential of the specific agents employed, patient characteristics such as age and sex also contribute. Recent clinical studies show that treatment with the currently available 5‐HT3 antagonists effectively reduces the incidence of chemotherapy‐induced nausea and vomiting and improves quality of life in a substantial number of these patients.
A Medline search from 1994 through February 1998 identified clinical trials that included previously untreated breast cancer patients using antiemetic therapy such as granisetron, ondansetron, dolasetron, and metoclopramide.
The studies reviewed here indicate that the antiemetic efficacy of 5‐HT3 antagonists is equivalent in previously untreated patients receiving moderately emetogenic chemotherapy for breast cancer, depending on the doses and schedules utilized. In particular, two comparative studies of granisetron and ondansetron with specific data for breast cancer patients showed that both agents eliminate nausea in approximately 50%, and vomiting in 60–70% of these patients, with the higher values observed when steroids were added to the 5‐HT3 receptor antagonist regimen.
Although the chemotherapy regimens employed for breast cancer are considered only moderately emetogenic, these regimens account for 60–90% of patients experiencing nausea and vomiting. The most recent clinical studies demonstrate that 5‐HT3 antagonists can significantly reduce the incidence of nausea in breast cancer patients receiving moderately emetogenic chemotherapy and should be employed in this setting.
Similar content being viewed by others
References
Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 48: 6–29, 1998
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103–109, 1997
Morrow GR: Chemotherapy-related nausea and vomiting: etiology and management. CA Cancer J Clin 39: 89–104, 1989
Perez EA, Hartmann LC: Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol 23(5 suppl 11): 41–45, 1996
Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K, Yocom K: A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 78: 144–151, 1996
De Mulder PHM, Seynaeve C, Vermorken JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P, Verweij J: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113: 834–840, 1990
Hesketh P: Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Semin Oncol 22(4 suppl 10): 19–23, 1995
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C: Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: multicenter, double-blind, randomized parallel study. J Clin Oncol 16: 754–760, 1998
Heron JF: Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Semin Oncol 22(suppl 10): 24–30, 1995
Fisher B, Osborne CK, Margolese RG, Bloomer WD: Neoplasms of the breast. In: Holland JF, Bast RC, Morton DL (eds) Cancer Medicine. Williams & Wilkins, Baltimore, MD, 1997, pp. 2349–2429
Tortorice PV, O'Connell MB: Management of chemotherapyinduced nausea and vomiting. Pharmacotherapy 10: 129–145, 1990
Frakes LA, Brehm TL, Kosty MP, Miller WE, McMillan RL, Mason J, Meisenberg BR: An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant. Bone Marrow Transplant 20: 473–478, 1997
Perez EA, Lembersky B, Kaywin P, Kalman L, Yocom K, Friedman C: Comparable safety and antiemetic efficacy of a brief (30-sec bolus) intravenous granisetron infusion and a standard (15-min) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Cancer J Sci Am 4: 52–58, 1998
Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B: Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27: 1137–1140, 1991
Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118: 407–413, 1993
Beck TM, York M, Chang A, Navari R, Harvey WH, Meshad M, Griffin D, Wentz A: Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Cancer Invest 15: 297–303, 1997
Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin JP, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C: Phase III doubleblind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 15: 2966–2973, 1997
Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Riviere A, Khayat D, Bleiberg H, Faraldi M, Claverie N: A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer 32A: 807–813, 1996
Gebbia V, Cannata G, Testa A, Curto G, Valenza R, Cipolla C, Latteri MA, Gebbia N: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer 74: 1945–1952, 1994
Italian Group for Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6: 805–810, 1995
Bleiberg HH, Spielmann M, Falkson G, Romain D: Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther 17: 38–51, 1995
Coates A, Abraham S, Kay SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203–208, 1983
Jenns K: Importance of nausea. Cancer Nurs 17: 488–493, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perez, E.A. 5‐HT3 antiemetic therapy for patients with breast cancer. Breast Cancer Res Treat 57, 207–214 (1999). https://doi.org/10.1023/A:1006233802863
Issue Date:
DOI: https://doi.org/10.1023/A:1006233802863